US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Helvetia Baloise Holding AG (0ACB) 銘柄情報

Helvetia Baloise Holding AG (0ACB)

0.00

0.00

(0.00%)

終了 6月10日 12:30AM

Helvetia Baloise Holding AG (0ACB) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

-

( - )

買値

0.00

売値

0.00

出来高

22,114

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

0.00

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

CHF 181,642

発行済株式数

99,062,896

配当利回り

7.7 (3.67%)

PER

19.2

1 株当たり利益 (EPS)

10.32

歳入

10.32B

純利益

552.3M

Helvetia Baloise Holding AG engages in life and non-life insurance, and reinsurance business. It offers life insurance products in the areas of investment-linked, group life, and traditional individual life others; non-life insurance products in the areas of property, motor vehicle, health/accident,... Helvetia Baloise Holding AG engages in life and non-life insurance, and reinsurance business. It offers life insurance products in the areas of investment-linked, group life, and traditional individual life others; non-life insurance products in the areas of property, motor vehicle, health/accident, liability, engineering, and transport; and pure risk, savings, endowment, and annuity insurance products, as well as pension plans and asset management services. The company also provides marine, aviation, and art insurance. It operates in Switzerland, Spain, Germany, Belgium, Luxembourg, Italian and Austrian Markets, France, and internationally The company was formerly known as Helvetia Holding AG and changed its name to Helvetia Baloise Holding AG in April 2022. Helvetia Baloise Holding AG was incorporated in 2017 and is headquartered in Basel, Switzerland. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.helvetia-baloise.com

本社

Basel, Switzerland

設立

2026

Helvetia Baloise Holding AG is listed in the sector of the ロンドン証券取引所 with ticker 0ACB. The last closing price for Helvetia Baloise was CHF0. Over the last year, Helvetia Baloise shares have traded in a share price range of CHF 0.00 to CHF 0.00.

Helvetia Baloise currently has 99,062,896 shares in issue. Helvetia Baloise has a price to earnings ratio (PE ratio) of 19.20.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0ACB - Frequently Asked Questions (FAQ)

What is the current Helvetia Baloise Holding AG share price?

The current share price of Helvetia Baloise Holding AG is CHF 0.00

How many Helvetia Baloise Holding AG shares are in issue?

Helvetia Baloise Holding AG has 99,062,896 shares in issue

What is the 1 year trading range for Helvetia Baloise Holding AG share price?

Helvetia Baloise Holding AG has traded in the range of CHF 0.00 to CHF 0.00 during the past year

What is the PE ratio of Helvetia Baloise Holding AG?

The price to earnings ratio of Helvetia Baloise Holding AG is 19.2

What is the cash to sales ratio of Helvetia Baloise Holding AG?

The cash to sales ratio of Helvetia Baloise Holding AG is 1.9

What is the registered address of Helvetia Baloise Holding AG?

The registered address for Helvetia Baloise Holding AG is Aeschengraben 21, Basel, Basel-Stadt, 4051

What is the Helvetia Baloise Holding AG website address?

The website address for Helvetia Baloise Holding AG is www.helvetia-baloise.com

janice shell

janice shell 9分前

If you want to add to the real estate list, he told me he had a condo in New York.

I-Glow

I-Glow 13分前

You never read any filings and here are the facts.
I suspected he was pushed out, and the SEC filings completely validate that.
?Castellum (NYSE-American: CTM) filed an 8-K stating that Wright "resigned" effective December 31, 2025. While corporate PR always uses the standard "no disp

Toronto_Trader

Toronto_Trader 15分前

The OTCM data is messed up. The ~149M unrestricted common shares were posted on December 9/25 and the 20M restricted common shares were posted Feb 25/26. No share issuance has occured since.

The exception being the 200M for the Kendrick deal, due to close within the next 3 weeks and s

Flip it

Flip it 15分前

You know your technology, no question about it.

Very clear

shajandr

shajandr 23分前

"He would be way too young for that."
Dude ... dude ... George was 66 years old. That is nott "way too young to die".

CANCER CHARLIE was 60 when he stopped circulating hemoglobin-containing envelopes, and he lived seven (7) years after diagnosis. His widowed wife is 61 and has

Helter Skelter

Helter Skelter 24分前

AI Overview 👉️ Yes, Malikie keeps its first $200 million in gross recoveries, and BlackBerry (BB) only begins receiving a percentage of the profits after Malikie is "made whole".

What date did these 4 settlements happen?

AI

rcbindustry

rcbindustry 24分前

The sentiment around AVXL seems extremely negative right now, which is often when biotech stocks become the most interesting to watch. There are still plenty of unanswered questions, but I think the next meaningful update from management will be more important than the daily share price fluctuations

wildwertski

wildwertski 27分前

The changes look good, but are simply cosmetic. It’s still the same app it was before. Still waiting for the most basic problems to be fixed. I guess we’ll just have to wait and see. Hope he comes through and something good happens. Best to all,WW

MartinLutherKing

MartinLutherKing 27分前

Oh Hell Yes something is brewing alright, Let’s all hold hands and pray for news$$$

100lbStriper

100lbStriper 30分前

i called it would break 30mil short, now it looks like they want 40mil.......anything really significant comes out and this will sky rocket!!!

Uncleteddy

Uncleteddy 32分前

You also forgot to mention that it is highly speculated that Talisman Group (hedge fund) created and used SPV to acquire more than the 71% of TGLO that delfin already owns. Which leads everyone to believe the float is much smaller than it appears on the surface

cottonisking

cottonisking 33分前

⏰️🐎🐎🐎 How has a recent Supreme Court ruling shifted SEC disgorgement powers in a bankruptcy case? The June 2026 Supreme Court ruling as it relates to LBHI's bankruptcy.

The U.S. Supreme Court did not rule on a case combining both Securities and Exchange Commiss

Moneysign5

Moneysign5 34分前

Not gonna lie. I have mixed emotions about this haha

chas1

WHY DOES IT NOT LOOK LIKE WINNING ?

MarcoPolo4

MarcoPolo4 37分前

You can’t do anything to stop someone from using your patents until they have a product introduced into the marketplace. You have to prove infringement of patents regarding material structure, manufacture or usage. You can’t do that until a finished product is sold and used by a customer. Usually a

Viking61

Viking61 40分前

It’s been violated since the Net Worth Sweep.

ace65

Less than a month ago we were in the trips..so we have had traction.
Looks like it basing here for next leg up.

nwtf

Only thing suppressing trades is the lack of investors. Wake up.

Checksinthemail

Checksinthemail 42分前

Hera gives the FHFA one mission as conservator, and that is preserved and conserv and make solvent. Once that is completed the FHFA director‘s job is complete and the company should be released The companies are no longer independent and insulated from the president political reasoning if they have

jour_trader

jour_trader 47分前

Completely agree on the intrinsic. Waiting game simply gets old. Few weeks away from next cc.

rich2

someone posted "Rich" might chime in

I KNOW WHAT I OWN, A chance for a grand slam home run from a little stinky pinky mining stock about to explode

anxiously awaiting the next news release

Moe2001

Moe2001 54分前

Which chrome Microsoft chrome 🤣? Ahh you think your words are useful lmaoo . BCAP LETS MAKE HISTORY 📈💥💨

mrwrn2010

mrwrn2010 56分前

“You realize we’ve dropped like 20% on what equates to 0.0005% of total shares per trading sessions.”

Bingo. What I’ve also been thinking about today is this - we just got acceptance of the ANDA filing for Eliquis. The price jumped after the announcement on slightly more volume but ha

dewophile

dewophile 1時間前

Gsk retained some R and D in oncology and notably retained what became belantamab. I wonder if GSK gets back into oncology if belantamab didn’t show such promise (yet to be realized commercially). I feel like they bought tesaro to get some critical mass in oncology bc having just one drug launch is

Helvetia Baloise

STEER Technologies

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。